Enanta Pharmaceuticals, Inc. (ENTA) Financials
ENTA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 428.5 million | 236.6 million |
2023-09-30 | 462.3 million | 245.5 million |
2023-06-30 | 495.2 million | 257.4 million |
2023-03-31 | 326.4 million | 57.1 million |
ENTA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -25.8 million | 8.1 million |
2023-09-30 | -23.0 million | 6.7 million |
2023-06-30 | -34.3 million | 7.0 million |
2023-03-31 | -16.2 million | 7.4 million |
ENTA Net Income
No data available :(
ENTA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 337.2 million | - | 25.5 million |
2023-09-30 | 369.9 million | - | 26.5 million |
2023-06-30 | 386.6 million | - | 27.7 million |
2023-03-31 | 210.1 million | - | 28.0 million |
ENTA Shares Outstanding
ENTA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 787000 | 36.4 million | 16.5 million | - |
2023-09-30 | 1.4 million | 36.2 million | 13.8 million | - |
2023-06-30 | 2.2 million | 43.0 million | 12.6 million | - |
2023-03-31 | 2.4 million | 43.5 million | 13.8 million | - |
ENTA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 18.0 million | 642000 |
2023-09-30 | 18.9 million | 669000 |
2023-06-30 | 18.9 million | 651000 |
2023-03-31 | 17.8 million | 540000 |
ENTA
Price: $13.04
52 week price:
Earnings Per Share: -6.57 USD
P/E Ratio: -1.92
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 3045
Ebitda: 15.9 millionMarket Capitalization: 355.8 million